Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

Inclusion Criteria:

- Women between the ages of 18 to 70

- Meet DSM-IV (Diagnostic and Statistical Manual version IV) criteria for schizophrenia
or schizoaffective disorder based on SCID (Structured Clinical Interview for the
DSM-IV) interview

- Overweight, as defined with a BMI of equal to or greater than 27 kg/m² and continuing
weight gain in the past year above 2% of previous years total body weight

- Be on a stable dose of antipsychotic medication; i.e. at least one month with no
dosage change, and two months from an antipsychotic switch; 5) Deemed to be
symptomatically stable by the clinical staff in the last two months

Exclusion Criteria:

- Meet criteria for current alcohol or other substance dependence, opioid use for any
reason or positive urine drug screen for opiates

- A history of dementia, mental retardation or other neurological disorder that may
interfere with study ratings

- Not capable of giving informed consent for participation in this study

- Ongoing pregnancy

- Known sensitivity to naltrexone

- A medical disorder that is known to cause obesity

- Use of sibutramine, topiramate, amphetamines or over the counter weight remedies

- Impaired liver functions (greater than 3 times the upper limit of normal)

- Diagnosed with polycystic ovary syndrome

- Currently being treated with insulin

- Current use of Depo-Provera or any natural/synthetic hormone treatment known to cause
significant weight gain